{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:09Z","timestamp":1787387049291,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017117","name":"Denali Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03643-y","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:01:00Z","timestamp":1781254860000},"page":"4060-4078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Mucopolysaccharidosis Type\u00a0II in Young Children from the Caregiver\u2019s Perspective: A Qualitative Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Jessica","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Engmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Stanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Pokrzywinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"3643_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041258","author":"F D\u2019Avanzo","year":"2020","unstructured":"D\u2019Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type\u00a0II: one hundred years of research, diagnosis, and treatment. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21041258.","journal-title":"Int J Mol Sci"},{"key":"3643_CR2","volume-title":"GeneReviews\u00ae","author":"M Scarpa","year":"1993","unstructured":"Scarpa M, Lampe C. Mucopolysaccharidosis type\u00a0II. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle: University of Washington; 1993."},{"issue":"2","key":"3643_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jpeds.2011.03.019","volume":"159","author":"J Holt","year":"2011","unstructured":"Holt J, Poe MD, Escolar ML. Early clinical markers of central nervous system involvement in mucopolysaccharidosis type\u00a0II. J Pediatr. 2011;159(2):320-6 e2. https:\/\/doi.org\/10.1016\/j.jpeds.2011.03.019.","journal-title":"J Pediatr"},{"issue":"6","key":"3643_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/jmg.19.6.408","volume":"19","author":"ID Young","year":"1982","unstructured":"Young ID, Harper PS, Newcombe RG, Archer IM. A clinical and genetic study of Hunter\u2019s syndrome. 2. Differences between the mild and severe forms. J Med Genet. 1982;19(6):408\u201311. https:\/\/doi.org\/10.1136\/jmg.19.6.408.","journal-title":"J Med Genet"},{"issue":"4","key":"3643_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones SA, Almassy Z, Beck M, et al. Mortality and cause of death in mucopolysaccharidosis type\u00a0II\u2014a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32(4):534\u201343. https:\/\/doi.org\/10.1007\/s10545-009-1119-7.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3643_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0827-1","volume":"13","author":"HY Lin","year":"2018","unstructured":"Lin HY, Chuang CK, Chen MR, et al. Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type\u00a0II: data from the Hunter Outcome Survey (HOS). Orphanet J Rare Dis. 2018;13(1):89. https:\/\/doi.org\/10.1186\/s13023-018-0827-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3643_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2025.109284","volume":"146","author":"J Muenzer","year":"2025","unstructured":"Muenzer J, Botha J, Amartino H, et al. Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18\u00a0years: final report of the Hunter Outcome Survey. Mol Genet Metab. 2025;146(4):109284. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109284.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3643_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03464-8","volume":"20","author":"J Muenzer","year":"2025","unstructured":"Muenzer J, Amartino H, Giugliani R, et al. Unmet needs of adults living with mucopolysaccharidosis II: data from the Hunter Outcome Survey. Orphanet J Rare Dis. 2025;20(1):319. https:\/\/doi.org\/10.1186\/s13023-024-03464-8.","journal-title":"Orphanet J Rare Dis"},{"key":"3643_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100499","volume":"21","author":"T Conner","year":"2019","unstructured":"Conner T, Cook F, Fernandez V, Rangel-Miller V. An online survey of burden of illness in families with mucopolysaccharidosis type\u00a0II children in the United States. Mol Genet Metab Rep. 2019;21:100499. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100499.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"3643_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0140-3","volume":"3","author":"M Harrington","year":"2019","unstructured":"Harrington M, Hareendran A, Skalicky A, Wilson H, Clark M, Mikl J. Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the Caregiver Impact Questionnaire. J Patient Rep Outcomes. 2019;3(1):44. https:\/\/doi.org\/10.1186\/s41687-019-0140-3.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"3643_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03034-y","volume":"19","author":"KS Yee","year":"2024","unstructured":"Yee KS, Lewis S, Evans E, Romano C, Alexanderian D. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase\u00a02\/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II. Orphanet J Rare Dis. 2024;19(1):110. https:\/\/doi.org\/10.1186\/s13023-024-03034-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3643_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-018-0093-3","volume":"4","author":"M Chalasani","year":"2018","unstructured":"Chalasani M, Vaidya P, Mullin T. Enhancing the incorporation of the patient\u2019s voice in drug development and evaluation. Res Involv Engagem. 2018;4(1):10. https:\/\/doi.org\/10.1186\/s40900-018-0093-3.","journal-title":"Res Involv Engagem"},{"issue":"5","key":"3643_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40259-024-00675-0","volume":"38","author":"A Zanetti","year":"2024","unstructured":"Zanetti A, Tomanin R. Targeting neurological aspects of mucopolysaccharidosis type\u00a0II: enzyme replacement therapy and beyond. BioDrugs. 2024;38(5):639\u201355. https:\/\/doi.org\/10.1007\/s40259-024-00675-0.","journal-title":"BioDrugs"},{"key":"3643_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100845","volume":"30","author":"N Grant","year":"2022","unstructured":"Grant N, Sohn YB, Ellinwood NM, et al. Timing is everything: clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair. Mol Genet Metab Rep. 2022;30:100845. https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100845.","journal-title":"Mol Genet Metab Rep"},{"issue":"16","key":"3643_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168573","volume":"25","author":"W Al-Hertani","year":"2024","unstructured":"Al-Hertani W, Pathak RR, Evuarherhe O, et al. Intravenous Q for the treatment of mucopolysaccharidosis type\u00a0II: a systematic literature review. Int J Mol Sci. 2024;25(16):8573. https:\/\/doi.org\/10.3390\/ijms25168573.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3643_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12779","volume":"48","author":"JH Kwak","year":"2025","unstructured":"Kwak JH, Choi YJ, Kim S, Yang A. Long-term cardiovascular outcomes and mortality with enzyme replacement therapy in patients with mucopolysaccharidosis type\u00a0II. J Inherit Metab Dis. 2025;48(1):e12779. https:\/\/doi.org\/10.1002\/jimd.12779.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3643_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107709","volume":"140","author":"JH Seo","year":"2023","unstructured":"Seo JH, Kosuga M, Hamazaki T, Shintaku H, Okuyama T. Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type\u00a0II: final report of 5-year results from a Japanese open-label phase\u00a01\/2 study. Mol Genet Metab. 2023;140(4):107709. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107709.","journal-title":"Mol Genet Metab"},{"key":"3643_CR18","unstructured":"PMDA. Hunterase\u00ae ICV Injection 15\u00a0mg. Product Insert. Japan 2021. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/850372_3959423A1022_1_03. Accessed 20 Feb 2026"},{"key":"3643_CR19","unstructured":"PMDA. IZCARGO\u00ae(pabinafusp alfa)IZCARGO\u00ae for I.V. infusion 10mg, Product Insert, Japan 2021. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/530210_3959424D1023_1_03. Accessed 20 Feb 2026"},{"issue":"12","key":"3643_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244279","volume":"15","author":"E Mengel","year":"2020","unstructured":"Mengel E, Gaedeke J, Gothe H, et al. The patient journey of patients with Fabry disease, Gaucher disease and mucopolysaccharidosis type\u00a0II: a German-wide telephone survey. PLoS ONE. 2020;15(12):e0244279. https:\/\/doi.org\/10.1371\/journal.pone.0244279.","journal-title":"PLoS ONE"},{"issue":"4","key":"3643_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10897-014-9791-7","volume":"24","author":"M Needham","year":"2015","unstructured":"Needham M, Packman W, Quinn N, et al. Health-related quality of life in patients with MPS\u00a0II. J Genet Couns. 2015;24(4):635\u201344. https:\/\/doi.org\/10.1007\/s10897-014-9791-7.","journal-title":"J Genet Couns"},{"issue":"1","key":"3643_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-101","volume":"8","author":"M Raluy-Callado","year":"2013","unstructured":"Raluy-Callado M, Chen WH, Whiteman DA, Fang J, Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type\u00a0II) on health-related quality of life. Orphanet J Rare Dis. 2013;8(1):101. https:\/\/doi.org\/10.1186\/1750-1172-8-101.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3643_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042.","journal-title":"Int J Qual Health Care"},{"key":"3643_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2023.101005","volume":"37","author":"H Lau","year":"2023","unstructured":"Lau H, Harmatz P, Botha J, Audi J, Link B. Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: an analysis from the Hunter Outcome Survey. Mol Genet Metab Rep. 2023;37:101005. https:\/\/doi.org\/10.1016\/j.ymgmr.2023.101005.","journal-title":"Mol Genet Metab Rep"},{"issue":"Suppl 2","key":"3643_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-018-0550-5","volume":"44","author":"C Galimberti","year":"2018","unstructured":"Galimberti C, Madeo A, Di Rocco M, Fiumara A. Mucopolysaccharidoses: early diagnostic signs in infants and children. Ital J Pediatr. 2018;44(Suppl 2):133. https:\/\/doi.org\/10.1186\/s13052-018-0550-5.","journal-title":"Ital J Pediatr"},{"issue":"5","key":"3643_CR26","doi-asserted-by":"publisher","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","volume":"127","author":"JB Holt","year":"2011","unstructured":"Holt JB, Poe MD, Escolar ML. Natural progression of neurological disease in mucopolysaccharidosis type\u00a0II. Pediatrics. 2011;127(5):e1258\u201365. https:\/\/doi.org\/10.1542\/peds.2010-1274.","journal-title":"Pediatrics"},{"issue":"1","key":"3643_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03581-y","volume":"20","author":"J Dempsey","year":"2025","unstructured":"Dempsey J, Daniels J, Katiri R, et al. Prioritisation of head, neck, and respiratory outcomes in mucopolysaccharidosis type\u00a0II: lessons from a rare disease consensus exercise and comparison of parental and clinical priorities. Orphanet J Rare Dis. 2025;20(1):88. https:\/\/doi.org\/10.1186\/s13023-025-03581-y.","journal-title":"Orphanet J Rare Dis"},{"key":"3643_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgmr.2015.03.011","volume":"3","author":"R Parini","year":"2015","unstructured":"Parini R, Rigoldi M, Tedesco L, et al. Enzymatic replacement therapy for Hunter disease: up to 9\u00a0years experience with 17 patients. Mol Genet Metab Rep. 2015;3:65\u201374. https:\/\/doi.org\/10.1016\/j.ymgmr.2015.03.011.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03643-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03643-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03643-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:38Z","timestamp":1787385878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03643-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3643"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03643-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jessica Baldwin and Natalie Engmann are employees of Denali Therapeutics, which funded this study. Sonya Stanczyk and Robin Pokrzywinski are employees of Thermo Fisher Scientific and members of the PPD\u2122 Evidera\u2122 Patient Centered Research team, hired by Denali Therapeutics to consult on this project. Kristin McKay is an employee of Project Alive, which receives financial support from Denali Therapeutics through event sponsorships and grants.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. The study protocol and informed consent procedures were approved by Advarra Institutional Review Board (Columbia, MD, USA; Pro00040794). Prior to interviews, participating caregivers provided informed consent and consent to be audio recorded.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}